Cancer Care Ontario | Action Cancer Ontario

Les statistiques sur le cancer en Ontario 2024 représentent le cinquième d'une série de rapports qui fournissent des informations approfondies sur l'...

Dec 1969

Guidelines and Advice

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

Status: Current
ID: Guideline Endorsement C50-CIDAP-3

Mar 2025

Drug

selpercatinib

Other Name(s): Retevmo™

Quick Link(s): Drug Monograph, Patient Info Sheet

Dec 1969

Document

[PDF]

SerousOvarianCancerTreatmentPathwayMap.pdf

Dec 1969

Drug

atezolizumab (subcut)

Other Name(s): Tecentriq® SC

Quick Link(s): Drug Monograph, Patient Info Sheet

Dec 1969

Regimen

AVD+NIVL

Cancer Type:

Hematologic,

Lymphoma - Hodgkin

Show More Show more tags

, Show Less Show fewer tags

Intent: Curative

Drugs Used:

nivolumab (Unfunded),

, Collapse Show fewer tags

Quick Link(s):

Regimen Monograph

Document

[PDF]

Support-on-Your-Palliative-Care-Journey.pdf

Dec 1969

Document

[PDF]

Accompagnement-dans-votre-parcours-de-soins-palliatifs.pdf

Dec 1969

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Safe-to-Switch.png

Systemic-Treatment-Implementation-Plan-2024-2028-EN.pdf

Systemic-Treatment-Implementation-Plan-2024-2028-FR

Standardized-Adnexal-Masses-US-Reporting-Explanatory-Notes.pdf

Statistiques sur le cancer en Ontario 2024

An Endorsement of the 2023 International Stereotactic Radiosurgery Society’s (ISRS) Guideline: A Systematic Review Informing the Management of Symptomatic Brain Radiation Necrosis After Stereotactic Radiosurgery and ISRS Recommendations

selpercatinib

SerousOvarianCancerTreatmentPathwayMap.pdf

atezolizumab (subcut)

AVD+NIVL

Support-on-Your-Palliative-Care-Journey.pdf

Accompagnement-dans-votre-parcours-de-soins-palliatifs.pdf

Pages